- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00440804
Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA
February 23, 2007 updated by: Farmacon
Randomized, Double-Blind Study of Ibuprofen L-Lysine Intravenous Solution in Premature Infants for the Early Treatment of Patent Ductus Arteriosus
The purpose of this study is to determine the safety and effectiveness of ibuprofen l-lysine iv in premature infants in the early treatment of Patent Ductus Arteriosus.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The ductus arteriosus remains patent in about 40% to 80% of very low birth weight infants.
Early treatment by intravenous ibuprofen L-lysine (IV ibuprofen) has been suggested in preliminary studies to close the ductus and shorten hospital stay.
This study aims to determine the effect of early treatment with IV ibuprofen given to the very low birth weight infant with a non-symptomatic patent ductus arteriosus (PDA) at less than 72 hours of life to accelerate and maintain ductal closure, thereby reducing the need for rescue therapy.
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 7 months (Child)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Premature newborn infant of either gender with a birth weight of 500 to 1000 grams, appropriate for gestational age;
- Non-symptomatic PDA with evidence of ductal shunting documented by an echocardiogram (ECHO);
- Less than 72 hours of age at the time of randomization;
- If infant is one of a multiple birth, he/she is one of the two (2) oldest infants who meet the eligibility criteria;
- Consent form signed by parent.
Exclusion Criteria:
- Either major congenital malformations and/or chromosomal anomalies;
- Proven, severe congenital bacterial infection;
- Maternal antenatal nonsteroidal anti-inflammatory drug (NSAID) exposure < 72 hours prior to delivery;
- Treatment with pharmacological replacement steroid therapy at anytime since birth;
- Unremitting shock requiring very high doses of vasopressors (i.e. inability to maintain mean arterial blood pressure appropriate for gestational age ± 2 SD using volume and maximal vasopressor therapy as defined by the individual institution);
- Renal failure or oliguria defined as urine flow rate < 0.5 mL/kg/hr in the 8 hours prior to randomization (Anuria is acceptable if infant is in first 24 hours of life);
- Platelet count < 75,000/mm 3;
- Clinical bleeding tendency (i.e. oozing from puncture sites);
- Expected survival less than 48 hours in the opinion of the attending neonatologist;
- Participation in other clinical intervention trials. Exceptions may be made if approved by Medical Director or designee, RPD Pharmaceutical Department;
- Symptomatic PDA as documented by 3 of the following 5 criteria
- Bounding pulse
- Hyperdynamic precordium
- Pulmonary edema
- Increased cardiac silhouette
- Systolic murmur Or, in view of the neonatologist is deemed to have a hemodynamically significant ductus.
- Exposure to NSAIDs at any time since birth.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Primary Outcome Measures (Efficacy)
|
Secondary Outcome Measures
Outcome Measure |
---|
Exploratory outcomes:
|
Gastrointestinal function
|
Renal function
|
Hematology
|
Liver enzyme tests
|
Serum bilirubin
|
Respiratory function
|
Intraventricular hemorrhage
|
Pulmonary hemorrhage
|
Pulmonary hypertension
|
Ibuprofen concentrations
|
Prostanoid concentrations
|
CYP2C9 Genotyping
|
Follow-up Outcomes
|
Retinopathy of Prematurity
|
Bronchopulmonary dysplsia
|
Periventricular leukomalacia
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jacob V Aranda, MD, PhD
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2002
Study Completion
August 1, 2005
Study Registration Dates
First Submitted
February 23, 2007
First Submitted That Met QC Criteria
February 23, 2007
First Posted (Estimate)
February 27, 2007
Study Record Updates
Last Update Posted (Estimate)
February 27, 2007
Last Update Submitted That Met QC Criteria
February 23, 2007
Last Verified
February 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Congenital Abnormalities
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Ductus Arteriosus, Patent
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ibuprofen
Other Study ID Numbers
- FCR-00-01/CB88
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patent Ductus Arteriosus
-
PFM Medical, IncBright Research PartnersCompleted
-
Abbott Medical DevicesCompletedPatent Ductus Arteriosus (PDA)United States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedPatent Ductus Arteriosus | Patent Ductus Arteriosus After Premature Birth | Patent Ductus Arteriosus - Delayed ClosureItaly, United Kingdom
-
Nada YoussefCompletedPatent Ductus Arteriosus After Premature Birth | Patent Ductus Arteriosus Conservative ManagementEgypt
-
Ankara UniversityCompletedPatent Ductus Arteriosus in Preterm InfantsTurkey
-
Abbott Medical DevicesNo longer availablePatent | Ductus | Arteriosus
-
University of FlorenceCompletedDuctus Arteriosus, PatentItaly
-
National Taiwan University HospitalCompletedPatent Ductus Arteriosus
-
Rambam Health Care CampusCompletedDuctus Arteriosus, PatentIsrael
-
Soha mahmoud Hussien mahdyAssiut UniversityNot yet recruiting
Clinical Trials on ibuprofen l-lysine iv solution (NeoProfen (R) )
-
Mount Sinai Hospital, CanadaSunnybrook Health Sciences Centre; McMaster Children's Hospital; The Rotunda...RecruitingPatent Ductus Arteriosus After Premature BirthCanada, Ireland
-
Umeå UniversityCompleted
-
Valleywise HealthCompleted
-
BayerCompletedAcute Coronary SyndromeSpain, China, Germany, Russian Federation
-
Biomendi S.A.U.Pivotal S.L.Terminated
-
AbbVieTerminatedProgressive Supranuclear Palsy (PSP)United States, Australia, Canada, Italy, Japan
-
St. Jude Children's Research HospitalNational Cancer Institute (NCI); National Institute of General Medical Sciences... and other collaboratorsCompletedAcute Lymphoblastic LeukemiaUnited States
-
The University of QueenslandBaxter Healthcare Corporation; Health Research Council, New Zealand; Australian...CompletedEnd Stage Kidney Disease | Kidney Transplant; Complications | Delayed Graft FunctionAustralia, New Zealand
-
KAT General HospitalUnknownNeuromuscular BlockGreece
-
Roswell Park Cancer InstituteCelldex TherapeuticsCompletedAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Refractory Anemia | Blasts 30 Percent or Less of Bone Marrow Nucleated CellsUnited States